The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
A Randomized, Open-label, Multiple-dose and Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A in Male Subjects
In the register
The register attaches this trial to CKD-843 (Chong Kun Dang Pharmaceutical), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Chong Kun Dang Pharmaceutical
- Participants (registry)
- 41
- Start
- November 2022
- Primary completion
- September 2023
- Study completion
- October 2023
- Last registry update
- January 2024
- Countries
- South Korea
Conditions studied: Alopecia
Interventions: CKD-843 A 45mg(Multiple dose), CKD-843 A 45mg, CKD-843 A 55mg(Multiple dose), CKD-843 A 55mg, CKD-843-R
Other trials of CKD-843
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.